Literature DB >> 2919777

Selection of implantable narcotic delivery systems.

S D Waldman1, D W Coombs.   

Abstract

Intraspinal narcotics have dramatically influenced the way pain of malignant origin is managed. There has been a rapid acceptance of this modality within the anesthesia community to treat a wide variety of cancer pain problems. In tandem the development of various implantable narcotic delivery systems has complemented and facilitated the expanded role of intraspinal narcotics in the treatment of cancer pain. Appropriate patient selection is crucial if optimal results are to be achieved. Factors to be considered in patient selection should include the results of the preimplantation spinal narcotic trial, infection trial, infection and local conditions, hematologic status, physiologic and behavioral abnormalities, cost, patient support systems and life expectancy. By interfacing these factors with the unique profiles that each of the five types of implantable narcotic delivery systems offer, improved results both in terms of pain relief and patient satisfaction can be expected.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2919777

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

1.  [Dangers and complications in pain therapy with epidural and intrathecal catheters.].

Authors:  B Donner; M Tryba; M Strumpf; R Dertwinkel
Journal:  Schmerz       Date:  1995-10       Impact factor: 1.107

2.  [Continuous subcutaneous application of analgesics in a patient suffering from a head and neck tumor.].

Authors:  I Gralow; W von Hornstein
Journal:  Schmerz       Date:  1992-12       Impact factor: 1.107

3.  [Continuous subcutaneous buprenorphine application in the treatment of cancer pain.].

Authors:  I Gralow; W F von Hornstein; E Schleyer; W Hiddemann
Journal:  Schmerz       Date:  1995-05       Impact factor: 1.107

4.  [Pain therapy with implanted medication pumps for chronic pain.].

Authors:  U Dell; D Covic; E Singer; M Fendrich
Journal:  Schmerz       Date:  1991-03       Impact factor: 1.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.